Interleukin‐6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID‐TIMI 52 (Stabilization of Plaque Using Darapladib—Thrombolysis in Myocardial Infarction 52) Trial

BACKGROUND: Interleukin‐6 (IL‐6) is an inflammatory cytokine implicated in plaque instability in acute coronary syndrome (ACS). We aimed to evaluate the prognostic implications of IL‐6 post‐ACS. METHODS AND RESULTS: IL‐6 concentration was assessed at baseline in 4939 subjects in SOLID‐TIMI 52 (Stabi...

Descripción completa

Detalles Bibliográficos
Autores principales: Fanola, Christina L., Morrow, David A., Cannon, Christopher P., Jarolim, Petr, Lukas, Mary Ann, Bode, Christoph, Hochman, Judith S., Goodrich, Erica L., Braunwald, Eugene, O'Donoghue, Michelle L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721825/
https://www.ncbi.nlm.nih.gov/pubmed/29066436
http://dx.doi.org/10.1161/JAHA.117.005637

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721825/
https://www.ncbi.nlm.nih.gov/pubmed/29066436
http://dx.doi.org/10.1161/JAHA.117.005637

Ejemplares similares